Ceftibuten was more effective than cefaclor.

Clinical Use of Ceftibuten Because of its ?-lactamase steadiness and extended gram-negative compass compared with cefixime and cefuroxime (Tables I and II), ceftibuten has been evaluated in the communicating of AOM, amphetamine respiratory geographical area illegality (URTI) in children, lower respiratory piece of ground communication (LRTI) in adults, and UTIs.
AOM
Contempt the spirit of antibiotic-resistant pathogens in many geographic areas, AOM continues to be treated initially with amoxicillin, trimethoprim-sulfamethoxazole (TMP-SMX), or erythromycin-sulfisoxazole, primarily because these are effective, established, and inexpensive antibiotics.
The common causative organisms in AOM, mathematical group A Streptococcus (5%), H influenzae (25%), M catarrhalis (5% to 35%), and S pneumoniae (30% to 40%) appear to be clinically responsive to these first-line agents in more than 80% of cases. However, ?-lactamase-producing H influenzae and M catarrhalis may persist with communication failures after use of these first-line drugs.
Ceftibuten is voice in vitro against common AOM organisms (Table II), and entering into eye ear matter in AOM should be sufficient to exceed the MIC90 for the four discipline pathogens (except penicillin-resistant S pneumoniae ).

Ceftibuten was more effective than cefaclor against H influenzae (97% and 76%, respectively), including ?-lactamase-producing H influenzae .
Ceftibuten and cefaclor were similar in efficacy against M catarrhalis, whereas ceftibuten appeared less effective than cefaclor against S pneumoniae (80% and 95%, respectively).
No data on the rates of PR-SP were available from this contemplation.
Judging from the results of the above-mentioned studies, ceftibuten appears to be a reasonable option for treating AOM when initial therapy, such as amoxicillin, has failed and when S pneumoniae, particularly penicillin-resistant strains, are less likely to be involved.
This advance uses the fact military capability of ceftibuten against gram-negative organisms, particularly ?-lactamase producers that are frequently isolated from patients who either have recurrent infections while receiving antimicrobial prophylaxis for AOM or have persistent infections neglect recent first- or second-line communication for AOM.
Pharyngitis
In a effort that compared 10 days of ceftibuten (9 mg/kg/d) with penicillin V (25 mg/kg/d divided into 3 equal doses) for attention of set A ?-hemolytic streptococcal pharyngitis in patients 3 to 18 eld of age, the cure/improvement rate was gambler with ceftibuten than with penicillin V (97% vs 88%). In the subset of patients with scarlet anticipation, the cure/improvement rate (90% for ceftibuten-treated patients, 100% for penicillin V-treated patients) was not significantly different.
When all patients with pharyngitis and scarlet feverishness are considered, the quality in cure rate was significantly good with ceftibuten (97% ceftibuten and 89% penicillin, P < .01).
Thus, once-daily ceftibuten appears to be a reasonable second-line selection for grouping A streptococcal pharyngitis for patients who fail to respond or are allergic to the usual first-line drugs, penicillin and erythromycin.
This is a part of article Ceftibuten was more effective than cefaclor. Taken from "Ceclor Cefaclor Info" Information Blog